Combination Pills for Treatment of High Blood Pressure: Cost-effectiveness in The Asia Pacific Region

Emily R. Atkins*, Thomas Lung, Julie Redfern

*Corresponding author for this work

Research output: Contribution to journalEditorialResearch

Abstract

High blood pressure (BP) is the leading cause of preventable disease and death globally. Treatment of high BP substantially reduces major cardiovascular events, a 10 mmHg reduction in systolic BP (SBP) reduces the relative risk of coronary events by 22% and stroke by 41%. The World Health Organization estimates the global prevalence of high BP is 22% in adults, and prevalence is highest in low and middle income countries. Much of the global burden of high BP occurs in the Asia Pacific region, where almost 60% of the world's population reside; and, where affordability of treatment is vital to implementation.
Original languageEnglish
Pages (from-to)313-315
Number of pages3
JournalHeart Lung and Circulation
Volume26
Issue number4
DOIs
Publication statusPublished - 1 Apr 2017
Externally publishedYes

Fingerprint

Dive into the research topics of 'Combination Pills for Treatment of High Blood Pressure: Cost-effectiveness in The Asia Pacific Region'. Together they form a unique fingerprint.

Cite this